Mandate

Vinge advises Isofol in connection with its listing on Nasdaq Stockholm

Vinge has advised Isofol Medical AB in connection with its listing on Nasdaq Stockholm, with the first day of trading on 21 October 2021. The prospectus was approved by the Swedish Financial Supervisory Authority on 18 October 2021. Isofol has a market value corresponding to approximately SEK 1.5 billion.

Isofol is a biotech company in late clinical phase which develops arfolitixorin in order to improve standard treatment of 5-FE based chemotherapy, primarily for advanced colorectal cancer, by increasing tumour response and progression free survival.

Vinge’s team primarily consisted of Anders StridJenny Sandlund and Edin Agic (Capital Markets), Victor Ericsson and Emelie Svanberg (Tax), Anna Ståhlklo (Commercial Agreements), Alexander Lindeberg (IP) and Rebecka Hansson (Employment Law).

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025